ketorolac has been researched along with Allodynia in 30 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Consistent with the effects upon allodynia, both gabapentin and ketorolac produced a preference for the drug-paired compartment in the early phase of the K/BxN model, while gabapentin, but not ketorolac, resulted in a place preference during late phase." | 7.83 | The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation. ( Corr, M; McQueen, J; Park, HJ; Sandor, K; Svensson, CI; Woller, SA; Yaksh, TL, 2016) |
| "We previously reported that partial sciatic nerve ligation (PSNL) dramatically up-regulates cyclooxygenase 2 (COX2) in injured sciatic nerve, and local injection of the COX inhibitor, ketorolac, reverses tactile allodynia and suppresses increased phosphorylation of the transcription factor cAMP responsive element binding protein [Eur J Neurosci 15 (2002) 1037]." | 7.72 | Intraplantar injection of a cyclooxygenase inhibitor ketorolac reduces immunoreactivities of substance P, calcitonin gene-related peptide, and dynorphin in the dorsal horn of rats with nerve injury or inflammation. ( Eisenach, JC; Ma, W, 2003) |
| "Pretreatment with parecoxib or ketorolac reduced the postinfusion area of pinprick hyperalgesia (P < 0." | 6.76 | Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans. ( Draegni, T; Heyerdahl, F; Lenz, H; Raeder, J; Schmelz, M; Stubhaug, A, 2011) |
| "Treatment with morphine (1mg/kg, s." | 5.38 | Involvement of inflammation in severe post-operative pain demonstrated by pre-surgical and post-surgical treatment with piroxicam and ketorolac. ( Fujita, I; Kita, Y; Okumura, T; Sakakibara, A, 2012) |
| " The aim was to explore the existence of a positive interaction between paracetamol 1 g and ketorolac 20 mg administered intravenously on experimental pain models in human beings." | 5.15 | A randomized, controlled trial validates a peripheral supra-additive antihyperalgesic effect of a paracetamol-ketorolac combination. ( Besson, M; Daali, Y; Dayer, P; Desmeules, J; Ing Lorenzini, K; Salomon, D, 2011) |
| " Because some non-steroidal anti-inflammatory drugs (NSAIDs) are structural analogs of prostaglandins and NSAIDs attenuate heat nociception and mechanical allodynia in models of inflammatory and neuropathic pain, we investigated whether three widely used NSAIDs (diclofenac, ketorolac, and xefocam) affect thermal and mechanical hyperalgesia following the activation of TRPA1 and TRPV1 channels." | 3.88 | Non-steroidal anti-inflammatory drugs attenuate agonist-evoked activation of transient receptor potential channels. ( Gurtskaia, G; Nozadze, I; Tsagareli, MG; Tsiklauri, N, 2018) |
| "Consistent with the effects upon allodynia, both gabapentin and ketorolac produced a preference for the drug-paired compartment in the early phase of the K/BxN model, while gabapentin, but not ketorolac, resulted in a place preference during late phase." | 3.83 | The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation. ( Corr, M; McQueen, J; Park, HJ; Sandor, K; Svensson, CI; Woller, SA; Yaksh, TL, 2016) |
| "We previously reported that partial sciatic nerve ligation (PSNL) dramatically up-regulates cyclooxygenase 2 (COX2) in injured sciatic nerve, and local injection of the COX inhibitor, ketorolac, reverses tactile allodynia and suppresses increased phosphorylation of the transcription factor cAMP responsive element binding protein [Eur J Neurosci 15 (2002) 1037]." | 3.72 | Intraplantar injection of a cyclooxygenase inhibitor ketorolac reduces immunoreactivities of substance P, calcitonin gene-related peptide, and dynorphin in the dorsal horn of rats with nerve injury or inflammation. ( Eisenach, JC; Ma, W, 2003) |
| "We previously reported the up-regulation of cyclooxygenase 2 (COX2) in injured sciatic nerve of rats with partial sciatic nerve ligation (PSNL) and the reversal of PSNL-elicited tactile allodynia by local injection of the COX inhibitor ketorolac [Eur J Neurosci 15 (2002) 1037]." | 3.72 | Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury. ( Eisenach, JC; Ma, W, 2003) |
| ") had no effect in two acute pain models, namely, the acetic acid-induced writhing (visceral pain) and the formalin test (tonic pain)." | 3.72 | Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. ( Jain, NK; Kulkarni, SK; Padi, SS; Singh, S, 2004) |
| " Local injection of ketorolac, a nonselective COX inhibitor, into the ipsilateral plantar side or into the injury site of the sciatic nerve, effectively reversed the tactile allodynia induced by PSNL for > 5 days." | 3.71 | Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. ( Eisenach, JC; Ma, W, 2002) |
| " In the present study, 4 weeks following partial sciatic nerve ligation, a single intrathecal injection of the cyclooxygenase (COX)-1 preferring inhibitor ketorolac (50 microg) significantly attenuated tactile allodynia for 6 days." | 3.71 | Role for both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injury. ( Du, W; Eisenach, JC; Ma, W, 2002) |
| "Adult migraineurs were randomized to ketorolac NS 31." | 2.82 | A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine. ( Dash, PD; Gelaye, B; Kurth, T; Nitchie, H; Peterlin, BL; Rao, AS, 2016) |
| "Pretreatment with parecoxib or ketorolac reduced the postinfusion area of pinprick hyperalgesia (P < 0." | 2.76 | Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans. ( Draegni, T; Heyerdahl, F; Lenz, H; Raeder, J; Schmelz, M; Stubhaug, A, 2011) |
| "Primary and secondary hyperalgesia were produced by a first-degree burn injury on abdominal skin 45 min before injection of the test medicines." | 2.73 | Methylprednisolone and ketorolac rapidly reduce hyperalgesia around a skin burn injury and increase pressure pain thresholds. ( Breivik, H; Kaasa, T; Romundstad, L; Stubhaug, A, 2007) |
| "Cutaneous allodynia and dysesthesia were then mapped and thermal and mechanical thresholds were measured." | 2.72 | The effect of intravenous ketorolac on capsaicin-induced deep tissue hyperalgesia. ( Kumar, K; Polston, GR; Wallace, MS, 2006) |
| "Forepaw mechanical allodynia was measured for 7 days, and spinal cord tissue was immunolabeled for glial fibrillary acidic protein (GFAP) and PAR1 expression in the dorsal horn on day 7." | 1.39 | Ketorolac reduces spinal astrocytic activation and PAR1 expression associated with attenuation of pain after facet joint injury. ( Dong, L; Smith, JR; Winkelstein, BA, 2013) |
| "Treatment with morphine (1mg/kg, s." | 1.38 | Involvement of inflammation in severe post-operative pain demonstrated by pre-surgical and post-surgical treatment with piroxicam and ketorolac. ( Fujita, I; Kita, Y; Okumura, T; Sakakibara, A, 2012) |
| "The opiate tolerance was complicated by tactile hyperalgesia at the site of the surgical wound." | 1.35 | [Acute opiate tolerance and postoperative hyperalgesia after a brief infusion of remifentanil managed with multimodal analgesia]. ( Cortiñas Sáenz, M; Cortiñas Sáenz, ML; Gerónimo Pardo, M; Hernández Vallecillo, MT; Ibarra Martí, ML; Mateo Cerdán, CM, 2008) |
| "Lipopolysaccharide (LPS)-induced hyperalgesia and the role of cyclooxygenase (COX) isoforms in acute and chronic nociceptive assays have been well established." | 1.33 | Role of cyclooxygenase-2 in lipopolysaccharide-induced hyperalgesia in formalin test. ( Kulkarni, SK; Padi, SS, 2005) |
| " Footpad PG levels returned to base line or below within 5 min of dosing with ketorolac, which suggests rapid turnover of PG in the inflamed tissue." | 1.30 | Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. ( Isakson, PC; Portanova, J; Seibert, K; Shaffer, A; Zhang, Y, 1997) |
| "Neuropathic pain was induced by tight ligation of the L5 and L6 spinal nerves." | 1.30 | Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats. ( Hunter, JC; Lashbrook, JM; Ossipov, MH; Porreca, F; Raffa, RB; Tallarida, RJ, 1999) |
| "Pretreatment with ketorolac had a selective effect on the postburn injury hyperalgesia, reducing the increase in pain intensity (P<0." | 1.29 | Reduction of postburn hyperalgesia after local injection of ketorolac in healthy volunteers. ( Brull, SJ; Collins, JG; Kitahata, LM; LaMotte, R; Lundell, JC; O'Connor, TZ; Silverman, DG, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (16.67) | 18.2507 |
| 2000's | 14 (46.67) | 29.6817 |
| 2010's | 11 (36.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsagareli, MG | 1 |
| Nozadze, I | 1 |
| Tsiklauri, N | 1 |
| Gurtskaia, G | 1 |
| Eisenach, JC | 6 |
| Tong, C | 1 |
| Curry, RS | 1 |
| Park, HJ | 1 |
| Sandor, K | 1 |
| McQueen, J | 1 |
| Woller, SA | 1 |
| Svensson, CI | 1 |
| Corr, M | 1 |
| Yaksh, TL | 2 |
| Rao, AS | 1 |
| Gelaye, B | 1 |
| Kurth, T | 1 |
| Dash, PD | 1 |
| Nitchie, H | 1 |
| Peterlin, BL | 1 |
| Ko, JS | 1 |
| Eddinger, KA | 1 |
| Angert, M | 1 |
| Chernov, AV | 1 |
| Dolkas, J | 1 |
| Strongin, AY | 1 |
| Shubayev, VI | 1 |
| Guzmán-Priego, CG | 1 |
| Méndez-Mena, R | 1 |
| Baños-González, MA | 1 |
| Araiza-Saldaña, CI | 1 |
| Castañeda-Corral, G | 1 |
| Torres-López, JE | 1 |
| Lenz, H | 1 |
| Raeder, J | 1 |
| Draegni, T | 1 |
| Heyerdahl, F | 1 |
| Schmelz, M | 1 |
| Stubhaug, A | 2 |
| Ing Lorenzini, K | 2 |
| Besson, M | 2 |
| Daali, Y | 2 |
| Salomon, D | 2 |
| Dayer, P | 2 |
| Desmeules, J | 2 |
| Fujita, I | 1 |
| Okumura, T | 1 |
| Sakakibara, A | 1 |
| Kita, Y | 1 |
| Dong, L | 1 |
| Smith, JR | 1 |
| Winkelstein, BA | 1 |
| Kang, YJ | 1 |
| Vincler, M | 1 |
| Li, X | 1 |
| Conklin, D | 1 |
| Ma, W | 4 |
| Padi, SS | 2 |
| Jain, NK | 1 |
| Singh, S | 1 |
| Kulkarni, SK | 2 |
| Hsueh, SF | 1 |
| Lu, CY | 1 |
| Chao, CS | 1 |
| Tan, PH | 1 |
| Huang, YW | 1 |
| Hsieh, SW | 1 |
| Hsiao, HT | 1 |
| Chung, NC | 1 |
| Lin, SH | 1 |
| Huang, PL | 1 |
| Lyu, PC | 1 |
| Yang, LC | 1 |
| Dunbar, SA | 1 |
| Karamian, I | 1 |
| Zhang, J | 1 |
| Kumar, K | 1 |
| Polston, GR | 1 |
| Wallace, MS | 1 |
| Romundstad, L | 1 |
| Kaasa, T | 1 |
| Breivik, H | 1 |
| Lee, IO | 1 |
| Seo, Y | 1 |
| Cortiñas Sáenz, M | 1 |
| Gerónimo Pardo, M | 1 |
| Cortiñas Sáenz, ML | 1 |
| Hernández Vallecillo, MT | 1 |
| Ibarra Martí, ML | 1 |
| Mateo Cerdán, CM | 1 |
| Møiniche, S | 1 |
| Pedersen, JL | 1 |
| Kehlet, H | 1 |
| Lundell, JC | 1 |
| Silverman, DG | 1 |
| Brull, SJ | 1 |
| O'Connor, TZ | 1 |
| Kitahata, LM | 1 |
| Collins, JG | 1 |
| LaMotte, R | 1 |
| Zhang, Y | 1 |
| Shaffer, A | 1 |
| Portanova, J | 1 |
| Seibert, K | 1 |
| Isakson, PC | 1 |
| Southall, DM | 1 |
| Michael, LR | 1 |
| Vasko, RM | 1 |
| Lashbrook, JM | 1 |
| Ossipov, MH | 1 |
| Hunter, JC | 1 |
| Raffa, RB | 1 |
| Tallarida, RJ | 1 |
| Porreca, F | 1 |
| Brandt, MR | 1 |
| Furness, MS | 1 |
| Mello, NK | 1 |
| Rice, KC | 1 |
| Negus, SS | 1 |
| Du, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (The KSPN Migraine Study)[NCT01807234] | Phase 4 | 72 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Can Opioid-induced Hyperalgesia be Prevented by Gradual Dose Reduction vs. Abrupt Withdrawal of Remifentanil?[NCT01702389] | Phase 4 | 16 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome was 2-hour headache relief; headache relief was defined as headache pain from moderate or severe pain to none or mild pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Ketorolac/ Placebo | 72.5 |
| Sumatriptan/ Placebo | 69.4 |
| Ketorolac Placebo/ Sumatriptan Placebo | 38.8 |
5) Absence of allodynia The presence of allodynia was assessed based on a series of 8 questions inquiring as to the presence of allodynia. Participants answering 2 or more questions positively were considered to have allodynia. (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 70.5 |
| Sumatriptan/ Placebo | 75.5 |
| Ketorolac Placebo/ Sumatriptan Placebo | 69.0 |
4) Defined as reduction of nausea to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 82.7 |
| Sumatriptan/ Placebo | 74.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 66.0 |
3) Defined as reduction of phonophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 75.0 |
| Sumatriptan/Placebo | 66.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 56.0 |
2) Defined as reduction of photophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 65.4 |
| Sumatriptan/ Placebo | 64.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 46.0 |
1) Pain Freedom: Pain Freedom at 2 hours is defined as being free of pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 43.1 |
| Sumatriptan/Placebo | 36.7 |
| Ketorolac Placebo/ Sumatriptan Placebo | 18.4 |
Participants' self-assessment of disability was assessed using 4-point scales (none, mild, moderate, and severe). A binary outcome variable was created grouping none and mild vs moderate to severe. . (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 1.9 |
| Sumatriptan/ Placebo | 8.1 |
| Ketorolac Placebo/ Sumatriptan Placebo | 10.2 |
8) 24 and 48 hours sustained pain freedom (SPF); Defined as the reduction of pain to none. Pain was assessed using a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 24 and 48 hours
| Intervention | percentage of patients (Number) | |
|---|---|---|
| 24 hour sustained pain freedom | 48 hour sustained pain freedom | |
| Ketorolac Placebo/ Sumatriptan Placebo | 12.2 | 12.2 |
| Ketorolac/ Placebo | 35.3 | 33.3 |
| Sumatriptan/ Placebo | 22.4 | 18.4 |
7) 24 and 48 hours sustained pain relief (SPR) Defined as the reduction of pain to none or mild from moderate or severe, on a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 24 and 48 hours
| Intervention | percentage of patients (Number) | |
|---|---|---|
| 24 hour sustained pain relief | 48 hour sustained pain relief | |
| Ketorolac Placebo/ Sumatriptan Placebo | 20.4 | 20.4 |
| Ketorolac/ Placebo | 49.0 | 49.0 |
| Sumatriptan/ Placebo | 40.8 | 30.6 |
9) The time, in minutes, will be measured from the time study drug is taken to the time when significant pain relief is first observed and maintained through 2 hours with no rescue medication use at or prior to this point. (NCT01807234)
Timeframe: following each treated migraine attack
| Intervention | percentage of patients (Number) | ||||
|---|---|---|---|---|---|
| 10 minutes | 15 minutes | 20 minutes | 30 minutes | 1 hour | |
| Ketorolac Placebo/ Sumatriptan Placebo | 12.2 | 14.3 | 22.4 | 26.5 | 32.6 |
| Ketorolac/ Placebo | 15.7 | 35.3 | 43.1 | 54.9 | 58.8 |
| Sumatriptan/ Placebo | 14.3 | 36.0 | 44.9 | 53.1 | 57.1 |
8 trials available for ketorolac and Allodynia
| Article | Year |
|---|---|
Failure of intrathecal ketorolac to reduce remifentanil-induced postinfusion hyperalgesia in humans.
Topics: Adult; Analgesics, Opioid; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Hot Temperature; | 2015 |
A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Disability Evaluation; Double-Bl | 2016 |
Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans.
Topics: Adult; Analgesics, Opioid; Blood Pressure; Cross-Over Studies; Cyclooxygenase Inhibitors; Double-Bli | 2011 |
A randomized, controlled trial validates a peripheral supra-additive antihyperalgesic effect of a paracetamol-ketorolac combination.
Topics: Acetaminophen; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Cross-Over | 2011 |
Validation of the simplified UVB model to assess the pharmacodynamics of analgesics in healthy human volunteers.
Topics: Acetaminophen; Adult; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; | 2012 |
The effect of intravenous ketorolac on capsaicin-induced deep tissue hyperalgesia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Cross-Over Studies; Double-Blind Method; | 2006 |
Methylprednisolone and ketorolac rapidly reduce hyperalgesia around a skin burn injury and increase pressure pain thresholds.
Topics: Adult; Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Burns; Cross-Over Studies; Double-Blind M | 2007 |
Topical ketorolac has no antinociceptive or anti-inflammatory effect in thermal injury.
Topics: Administration, Topical; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; B | 1994 |
22 other studies available for ketorolac and Allodynia
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs attenuate agonist-evoked activation of transient receptor potential channels.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Diclofenac; Disease Models, | 2018 |
The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation.
Topics: Amines; Analgesics; Animals; Arthritis; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapen | 2016 |
Spinal activity of interleukin 6 mediates myelin basic protein-induced allodynia.
Topics: Amines; Animals; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Cyclooxygenase Inhibitors; D | 2016 |
Antihyperalgesic Effects of Indomethacin, Ketorolac, and Metamizole in Rats: Effects of Metformin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Dipyrone; Dose-Response Relationship, | 2017 |
Involvement of inflammation in severe post-operative pain demonstrated by pre-surgical and post-surgical treatment with piroxicam and ketorolac.
Topics: Analgesics, Opioid; Animals; Cyclooxygenase Inhibitors; Disease Models, Animal; Edema; Hyperalgesia; | 2012 |
Ketorolac reduces spinal astrocytic activation and PAR1 expression associated with attenuation of pain after facet joint injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Glial Fibrillary Acidic Protein; Hyper | 2013 |
Intrathecal ketorolac reverses hypersensitivity following acute fentanyl exposure.
Topics: Anesthetics, Intravenous; Animals; Cyclooxygenase Inhibitors; Drug Hypersensitivity; Fentanyl; Hyper | 2002 |
Intraplantar injection of a cyclooxygenase inhibitor ketorolac reduces immunoreactivities of substance P, calcitonin gene-related peptide, and dynorphin in the dorsal horn of rats with nerve injury or inflammation.
Topics: Animals; Behavior, Animal; Calcitonin Gene-Related Peptide; Carrageenan; Cell Count; Cyclooxygenase | 2003 |
Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury.
Topics: Animals; Behavior, Animal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 2003 |
Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor.
Topics: Acetic Acid; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2004 |
Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2004 |
Role of cyclooxygenase-2 in lipopolysaccharide-induced hyperalgesia in formalin test.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dexamethasone; Di | 2005 |
Ketorolac prevents recurrent withdrawal induced hyperalgesia but does not inhibit tolerance to spinal morphine in the rat.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-R | 2007 |
The effects of intrathecal cyclooxygenase-1, cyclooxygenase-2, or nonselective inhibitors on pain behavior and spinal Fos-like immunoreactivity.
Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor | 2008 |
[Acute opiate tolerance and postoperative hyperalgesia after a brief infusion of remifentanil managed with multimodal analgesia].
Topics: Acetaminophen; Adnexal Diseases; Amides; Analgesia, Epidural; Analgesics, Non-Narcotic; Analgesics, | 2008 |
Reduction of postburn hyperalgesia after local injection of ketorolac in healthy volunteers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bradykinin; Burns; Humans; Hyperalgesia; Injections, Intrad | 1996 |
Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production.
Topics: Animals; Cyclooxygenase Inhibitors; Dinoprostone; Hyperalgesia; Inflammation; Ketorolac; Male; Rats; | 1997 |
Intrathecal NSAIDS attenuate inflammation-induced neuropeptide release from rat spinal cord slices.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Cyclooxygenase Inhibitors; Freund's Adj | 1998 |
Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats.
Topics: Analgesics, Opioid; Animals; Cyclooxygenase Inhibitors; Drug Synergism; Hyperalgesia; Injections, Sp | 1999 |
Antinociceptive effects of delta-opioid agonists in Rhesus monkeys: effects on chemically induced thermal hypersensitivity.
Topics: Analgesics; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Capsai | 2001 |
Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain.
Topics: Animals; Cyclic AMP Response Element-Binding Protein; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2002 |
Role for both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injury.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2002 |